WO1999047543A3 - Sustained-release composition including amorphous polymer - Google Patents

Sustained-release composition including amorphous polymer Download PDF

Info

Publication number
WO1999047543A3
WO1999047543A3 PCT/US1999/006198 US9906198W WO9947543A3 WO 1999047543 A3 WO1999047543 A3 WO 1999047543A3 US 9906198 W US9906198 W US 9906198W WO 9947543 A3 WO9947543 A3 WO 9947543A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
sustained
composition including
release composition
amorphous polymer
Prior art date
Application number
PCT/US1999/006198
Other languages
French (fr)
Other versions
WO1999047543A2 (en
Inventor
Theodore W Randolph
Mark C Manning
Richard F Falk
Original Assignee
Univ Technology Corp
Theodore W Randolph
Mark C Manning
Richard F Falk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Technology Corp, Theodore W Randolph, Mark C Manning, Richard F Falk filed Critical Univ Technology Corp
Priority to AU31082/99A priority Critical patent/AU3108299A/en
Priority to EP99912785A priority patent/EP1073419A4/en
Priority to JP2000536736A priority patent/JP2002506876A/en
Priority to CA002324254A priority patent/CA2324254C/en
Publication of WO1999047543A2 publication Critical patent/WO1999047543A2/en
Publication of WO1999047543A3 publication Critical patent/WO1999047543A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Abstract

Provided is a sustained release composition for sustained release of a pharmaceutical substance. The composition includes a biocompatible polymer that is highly amorphous and a pharmaceutical substance in a hydrophobic ion complex with an amphiphilic material. Also provided a compressed antisolvent method for manufacturing the composition, various product forms incorporating the composition and various uses for the composition.
PCT/US1999/006198 1998-03-18 1999-03-18 Sustained-release composition including amorphous polymer WO1999047543A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU31082/99A AU3108299A (en) 1998-03-18 1999-03-18 Sustained-release composition including amorphous polymer
EP99912785A EP1073419A4 (en) 1998-03-18 1999-03-18 Sustained-release composition including amorphous polymer
JP2000536736A JP2002506876A (en) 1998-03-18 1999-03-18 Sustained release composition comprising an amorphous polymer
CA002324254A CA2324254C (en) 1998-03-18 1999-03-18 Sustained-release composition including amorphous polymer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7839098P 1998-03-18 1998-03-18
US60/078,390 1998-03-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09403412 A-371-Of-International 2000-03-08
US09/877,330 Continuation US6613358B2 (en) 1998-03-18 2001-06-07 Sustained-release composition including amorphous polymer

Publications (2)

Publication Number Publication Date
WO1999047543A2 WO1999047543A2 (en) 1999-09-23
WO1999047543A3 true WO1999047543A3 (en) 1999-11-04

Family

ID=22143753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006198 WO1999047543A2 (en) 1998-03-18 1999-03-18 Sustained-release composition including amorphous polymer

Country Status (5)

Country Link
EP (1) EP1073419A4 (en)
JP (1) JP2002506876A (en)
AU (1) AU3108299A (en)
CA (1) CA2324254C (en)
WO (1) WO1999047543A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815540B1 (en) † 2000-10-19 2005-06-10 Separex Sa PROCESS FOR MANUFACTURING VERY FINE PARTICLES COMPRISING A PRINCIPLE INSERTED IN A HOST MOLECULE
NZ530315A (en) * 2001-07-10 2007-01-26 Corixa Corp Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
GB0216780D0 (en) * 2002-07-19 2002-08-28 Bradford Particle Design Ltd Methods of particle formation
EP1452177A1 (en) * 2003-02-27 2004-09-01 Boehringer Ingelheim International GmbH Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent
US9682043B2 (en) 2003-12-09 2017-06-20 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
EP2500015A1 (en) 2006-12-05 2012-09-19 Landec Corporation Delivery of drugs
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
CN102131483A (en) 2008-02-08 2011-07-20 昌达生物科技公司 Non-polymeric compositions for controllable drug delivery
BR112016002342A8 (en) * 2013-08-06 2018-01-23 Dong Kook Pharm Co Ltd entecavir microsphere, method for preparation of an entecavir microsphere, and pharmaceutical composition
KR20170054459A (en) 2014-09-10 2017-05-17 더블 본드 파마슈티컬스 에이비 Targeted delivery of hydrophilic drugs
WO2017153052A1 (en) * 2016-03-07 2017-09-14 Double Bond Pharmaceuticals Ab Targeted delivery of hydrophilic drugs to lung

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526938A (en) * 1982-04-22 1985-07-02 Imperial Chemical Industries Plc Continuous release formulations
US4582820A (en) * 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
US5445832A (en) * 1991-07-22 1995-08-29 Debio Recherche Pharmaceutique S.A. Process for the preparation of microspheres made of a biodegradable polymeric material
US5770559A (en) * 1992-10-14 1998-06-23 The Regents Of The University Of Colorado Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0817620B1 (en) * 1995-03-28 2002-01-30 Fidia Advanced Biopolymers, S.R.L. Nanospheres comprising a biocompatible polysaccharide
AU2676397A (en) * 1996-04-18 1997-11-07 University Technology Corporation Methods for treating middle and inner ear disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526938A (en) * 1982-04-22 1985-07-02 Imperial Chemical Industries Plc Continuous release formulations
US4582820A (en) * 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
US5445832A (en) * 1991-07-22 1995-08-29 Debio Recherche Pharmaceutique S.A. Process for the preparation of microspheres made of a biodegradable polymeric material
US5770559A (en) * 1992-10-14 1998-06-23 The Regents Of The University Of Colorado Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1073419A4 *

Also Published As

Publication number Publication date
CA2324254C (en) 2005-01-04
JP2002506876A (en) 2002-03-05
WO1999047543A2 (en) 1999-09-23
EP1073419A2 (en) 2001-02-07
AU3108299A (en) 1999-10-11
CA2324254A1 (en) 1999-09-23
EP1073419A4 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
AU2034395A (en) Composition consisting of a dendrimer and an active substance occluded in the dendrimer, a process for the preparation of such a composition and a process for releasing the active substance
WO1999036099A8 (en) Sustained release compositions, process for producing the same and utilization thereof
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2208230A1 (en) Controlled release formulation (albuterol)
CA2079423A1 (en) Gradual release structures for chewing gum
AU679663B2 (en) Dermatological or pharmaceutical composition, preparation process and use
EP0761712A3 (en) Bioabsorbable polymer and process for preparing the same
AU6845300A (en) Novel multilayered material bearing a biologically active agent and the preparation thereof
CA2409292A1 (en) Tablets and methods for modified release of hydrophilic and other active agents
WO1999047543A3 (en) Sustained-release composition including amorphous polymer
WO2003061625A3 (en) Sustained release ophthalmological device and method of making and using the same
HUP9900311A2 (en) Water-redispersible powdered polymer composition, process for producing thereof, pseudolatex producable therefrom and their using
CA2227272A1 (en) Use of lipids as aids in the production of solid drug forms by melt extrusion
AU3957601A (en) Biologically active materials from cereals and process for preparation thereof
MXPA02009797A (en) Pharmaceutical preparations and their manufacture.
CA2374418A1 (en) Process for making a pipa-polyol
HUP9900332A3 (en) Water-redispersible powdered polymer compositions, process for producing thereof and pseudolatexs produced thereof and their using
PL312644A1 (en) Redispersible core-shell polymers in powdered form, their production and application
EP1002793A4 (en) Physiologically active substances tkr2449, process for producing the same, and microorganism
AU7040998A (en) Polysaccharide-based thermoplastic material, process for preparing the same and use thereof
WO1998025590A3 (en) Preparation in form of a matrix material-auxiliary agent compound containing optionally an active substance
CA2273272A1 (en) Immediate release drug delivery forms
AU4722597A (en) Water-soluble polymer, process for the production of the same, and use thereof as polymeric coagulant
CA2209673A1 (en) Solid medicament form with active agent distributed in polymer material
AU4845196A (en) 2-sulfinylnicotinamide derivatives, intermediate thereof, process for producing 2-sulfinylnicotinamide derivatives, and medicinal composition containing the same as active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09403412

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2324254

Country of ref document: CA

Ref country code: CA

Ref document number: 2324254

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 536736

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999912785

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999912785

Country of ref document: EP